These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31442475)

  • 1. The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms.
    Zhang WH; Wang WQ; Gao HL; Yu XJ; Liu L
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188311. PubMed ID: 31442475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications.
    Vitale G; Carra S; Ferraù F; Guadagno E; Faggiano A; Colao A;
    Crit Rev Oncol Hematol; 2020 Feb; 146():102840. PubMed ID: 31918344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
    Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
    Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Gastroenteropancreatic Neuroendocrine Neoplasia.
    Popa Ilie IR; Georgescu CE
    Neuroendocrinology; 2023; 113(2):262-278. PubMed ID: 34348340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Hasegawa S; Kobayashi N; Okubo N; Tokuhisa M; Goto A; Kurita Y; Sato T; Hosono K; Endo I; Nakajima A; Ichikawa Y
    Intern Med; 2021 Apr; 60(7):977-983. PubMed ID: 33162477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
    Weber MM; Fottner C
    Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms.
    Liu M; Zhang Y; Chen L; Lin Y; He Q; Zeng Y; Chen M; Chen J
    Endocrine; 2021 Jan; 71(1):242-252. PubMed ID: 33010002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.
    Ali AS; Langer SW; Federspiel B; Hjortland GO; Grønbæk H; Ladekarl M; Welin S; Weber Vestermark L; Arola J; Osterlund P; Knigge U; Sørbye H; Micke P; Grimelius L; Grönberg M; Tiensuu Janson E
    PLoS One; 2020; 15(12):e0243900. PubMed ID: 33315908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Alexandraki KI; Daskalakis K; Tsoli M; Grossman AB; Kaltsas GA
    Trends Endocrinol Metab; 2020 Mar; 31(3):239-255. PubMed ID: 31839442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs): The Role of Checkpoint Inhibitors.
    Arrivi G; Fazio N
    Curr Cancer Drug Targets; 2022 Aug; 22(8):629-638. PubMed ID: 35034595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
    Kaur J; Vijayvergia N
    Curr Oncol; 2023 Sep; 30(9):8653-8664. PubMed ID: 37754542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms.
    Herman Mahečić D; Cigrovski Berković M; Zjačić-Rotkvić V; Čačev T; Kapitanović S; Ulamec M
    Bosn J Basic Med Sci; 2020 Nov; 20(4):445-450. PubMed ID: 32156252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
    Ohmoto A; Morizane C
    Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
    Abdel-Rahman O; Fouad M
    Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.